Abstract 2323
Background
Cardiovascular diseases are one of the late effects of breast cancer treatment that can impair survival. We reviewed the development of cardiac disease in breast cancer survivor using nationwide database.
Methods
A nation-wide retrospective cohort study was conducted using National Health Information Database which provides a whole set of claimed medical information, such as ICD-10 diagnosis and prescription data. We performed 1:5 age-sex matching with the non-cancer controls. Incidence of MI and CHF was evaluated for adjuvant treatment modalities, with adjustment of age and previous comorbidities (diabetes, hypertension, and hyperlipidemia).
Results
A total of 112,058 cases (554,801 person-years) and 560,290 controls (2,916,459 person-years) were evaluated. Risk of MI (hazard ratio (HR) 1.258, 95% confidence interval (CI) 1.168 - 1.355) and CHF (HR 1.86, 95% CI 1.753 – 1.973) was higher in breast cancer survivors than in non-cancer controls. Younger survivors (age 50 or less) showed the highest risk of MI (HR 1.73, 95% CI 1.512 – 1.979) and CHF (HR 3.557, 95% CI 3.174 – 3.986). Within one year of breast cancer diagnosis, the cumulative incidences of MI and CHF were significantly high in survivors. The cumulative incidence of CHF in breast cancer survivors was continuously higher than the control group, in contrast to that of MI showed similar pattern to controls. Taxane use was associated with development of MI (HR 1.284, 95% CI 1.074 – 1.534) and CHF (HR 1.65, 95% CI 1.444 – 1.887).
Conclusions
Incidence of MI and CHF were higher in breast cancer survivor than the non-cancer controls. The elevated risk of MI and CHF in early phase of survivorship should be noted, especially in young age group.
Clinical trial identification
Legal entity responsible for the study
The Study of Multi-disciplinary Teamwork for breast cancer survivorship (SMARTSHIP).
Funding
Korean Breast Cancer Society.
Editorial Acknowledgement
The authors appreciate to the Korean Breast Cancer Society and the Study of Multi-dicsiplinary Teamwork for breast cancer survivorship (SMARTSHIP)
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
2595 - Real-Life Utilization of Genomic testing for invasive Breast Cancer patients in Italy and France reduces Chemotherapy Recommendations
Presenter: Sandro Barni
Session: Poster display session: Breast cancer - early stage, locally advanced & metastatic, CNS tumours, Developmental therapeutics, Genitourinary tumours - prostate & non-prostate, Palliative care, Psycho-oncology, Public health policy, Sarcoma, Supportive care
Resources:
Abstract
2343 - Benefit of adjuvant chemotherapy in hormone receptor-positive, HER2-negative, invasive lobular carcinoma of the breast
Presenter: Alexandre De Nonneville
Session: Poster display session: Breast cancer - early stage, locally advanced & metastatic, CNS tumours, Developmental therapeutics, Genitourinary tumours - prostate & non-prostate, Palliative care, Psycho-oncology, Public health policy, Sarcoma, Supportive care
Resources:
Abstract
2990 - Baseline lymphocyte counts predict distant recurrence in early breast cancer
Presenter: Gun Min Kim
Session: Poster display session: Breast cancer - early stage, locally advanced & metastatic, CNS tumours, Developmental therapeutics, Genitourinary tumours - prostate & non-prostate, Palliative care, Psycho-oncology, Public health policy, Sarcoma, Supportive care
Resources:
Abstract
4532 - A propensity score analysis exploring the impact of the addition of adjuvant chemotherapy (aCT) to hormone therapy (aHT) in a multi-center series of resected luminal early stage pure Invasive Lobular Breast Carcinoma (ILC).
Presenter: Luisa Carbognin
Session: Poster display session: Breast cancer - early stage, locally advanced & metastatic, CNS tumours, Developmental therapeutics, Genitourinary tumours - prostate & non-prostate, Palliative care, Psycho-oncology, Public health policy, Sarcoma, Supportive care
Resources:
Abstract
2344 - Benefit of Adjuvant Systemic Therapies in HR+ HER2- pT1ab Node-Negative Breast Carcinomas
Presenter: Alexandre De Nonneville
Session: Poster display session: Breast cancer - early stage, locally advanced & metastatic, CNS tumours, Developmental therapeutics, Genitourinary tumours - prostate & non-prostate, Palliative care, Psycho-oncology, Public health policy, Sarcoma, Supportive care
Resources:
Abstract
3525 - Anti-proliferative effect of oral metronomic vinorelbine in PAM50 Luminal/HER2-negative early breast cancer (SOLTI-1501 VENTANA): an open-label, randomized, three-arm, multicenter, window-of-opportunity study
Presenter: Aleix Prat
Session: Poster display session: Breast cancer - early stage, locally advanced & metastatic, CNS tumours, Developmental therapeutics, Genitourinary tumours - prostate & non-prostate, Palliative care, Psycho-oncology, Public health policy, Sarcoma, Supportive care
Resources:
Abstract
3908 - Clinicopathologic significance of androgen receptor expression and discordant receptor status during progression in breast cancer
Presenter: Chan Heun Park
Session: Poster display session: Breast cancer - early stage, locally advanced & metastatic, CNS tumours, Developmental therapeutics, Genitourinary tumours - prostate & non-prostate, Palliative care, Psycho-oncology, Public health policy, Sarcoma, Supportive care
Resources:
Abstract
4075 - The outcomes of early breast cancers utilizing the Oncotype Dx Recurrence score (RS) instead of Clinico-pathological (CP) factors for prognostic risk assessment: A Single Institution Experience
Presenter: Adhar Alsayed
Session: Poster display session: Breast cancer - early stage, locally advanced & metastatic, CNS tumours, Developmental therapeutics, Genitourinary tumours - prostate & non-prostate, Palliative care, Psycho-oncology, Public health policy, Sarcoma, Supportive care
Resources:
Abstract
738 - Circulating tumor cells as a prognostic marker in non metastatic breast cancer patients.
Presenter: Summar Elmorshidy
Session: Poster display session: Breast cancer - early stage, locally advanced & metastatic, CNS tumours, Developmental therapeutics, Genitourinary tumours - prostate & non-prostate, Palliative care, Psycho-oncology, Public health policy, Sarcoma, Supportive care
Resources:
Abstract
3151 - Molecular subtyping of breast cancer by dedicated breast PET
Presenter: Satoshi Sueoka
Session: Poster display session: Breast cancer - early stage, locally advanced & metastatic, CNS tumours, Developmental therapeutics, Genitourinary tumours - prostate & non-prostate, Palliative care, Psycho-oncology, Public health policy, Sarcoma, Supportive care
Resources:
Abstract